Cancer clinical trials in the region Île-de-France

684 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B5
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Pancreas cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B6
Required histologic sub types
Adenocarcinoma Other
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ATM
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B2
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Lung cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer #NCT06923761 #2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2 Lung cancer Prostate cancer Colon cancer Rectal cancer Liver and bile duct cancer Head and neck cancer #NCT06725758 #2022-503061-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Mesothelium Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses
Required histologic sub types
Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Orion Pharma
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06934538 #2024-512011-45-00
Phase 1 et Phase 2A Bras 2A-1
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS KRAS G12C KRAS non G12C MSS/pMMR KRAS G12D
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
5 recruiting sites
Brenus Pharma
Phase 1 / Phase 2 Lung cancer #NCT06162221
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS non G12C KRAS G12D NRAS
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06833008 #2024-519184-18-00
Required disease stage
Metastatic
Required genetic anomalies
Other KRAS BRAF KRAS G12C KRAS non G12C NRAS HRAS KRAS G12D
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Ipsen
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06819735
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Domain Therapeutics Australia Pty Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06154291 #2023-505266-29-00
Partie I: Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS